Dubai, 24 October 2012,
Stallergenes SA and Genpharm Services have announced today that they have signed an exclusive promotion agreement for Stallergenes’ range of allergen-immunotherapy (AIT) treatments in the UAE. “We are delighted to work with Genpharm in order to develop the Allergic Rhinitis & Allergic Asthma markets in the UAE” said Pavel Solsky, Export Director of Stallergenes. “We believe that its Evidenced based approach and its knowledge of the UAE pharmaceutical market will bring the necessary leverage to succeed in this growing therapeutic area. We anticipate a warm welcome from the medical community. With Genpharm’s support, we expect AIT to become the treatment of choice by specialists treating allergic patients.”
“We are delighted to enter into a strategic partnership with Stallergenes in the UAE. Stallergenes has been at the forefront of innovation, introducing the sublingual form of immunotherapy for Allergic Rhinitis and Allergic Asthma. Staloral® is already available and approved by the Ministry of Health in the UAE. We will work closely with all stakeholders in to increase awareness and improve the quality of life of patients suffering from this condition”, says Karim Smaira CEO of Genpharm Services.
Stallergenes is a European biopharmaceutical company specialized in the treatment by allergen immunotherapy of allergy related respiratory diseases, such as severe rhino-conjunctivitis and rhinitis, as well as allergic asthma. The seventh largest pharmaceutical company in France and the leader in sublingual immunotherapy treatment, Stallergenes devotes almost 20% of its gross turnover to Research & Development and is actively involved in the development of a new therapeutic class, sublingual immunotherapy tablets. In 2011, the company had sales of € 235 million and more than 500,000 patients were treated with Stallergenes products.
About GENPHARM Services
Genpharm Services is a pharmaceutical marketing company, based in the Dubai Biotechnology and Research Park, UAE.
Through Evidence based medicine, Genpharm provides healthcare organizations with innovative therapeutic solutions, in niche and rare genetic disease areas, market access strategies and sustainable commercial solutions, in the Middle East and North Africa Region.
For more information:
This document may contain forward-looking statements and estimates with respect to the anticipated future performance of Genpharm Services and the market in which it operates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond Genpharm Services’’ control. Therefore, actual results, the financial condition, performance or achievements of Genpharm Services, or industry results, may turn out to be materially different from any future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of the publication of this document. Genpharm Services disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in Genpharm Services expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by the UAE law.